4688美高梅

中国4688美高梅集团(股份)有限公司-官方网站

Press Releases

Pharma Sources Exclusive: Doer Biologics COO Dr. Fang Yongliang Unveils the Therapeutic Potential and Clinical Development of Triple Agonist DR10624

2026/07/23

Read more

EASL China Voice: DR10624 Phase II Results Show Significant Liver Fat Reduction and Metabolic Improvements in Severe Hypertriglyceridemia

2026/06/03

Read more

Dr. Yongliang Fang on Endpoints News：Chinese biotech unveils first-in-class tri-agonist for high lipids

2025/12/31

Read more

Doer Biologics' Globally First-in-Class Drug DR10624 Phase II Clinical Data Presented in Opening Session at AHA 2025

2025/11/11

Read more

Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

2025/03/12

Read more

Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media

2024/10/09

Read more

Many mainstream media reported the collaboration between Zhejiang Doer Biologics and MSD

2022/12/19

Read more

Reported by PR Newswire published

2022/12/17

Read more

Doer Biologics interview by Biopharma Reporter published

2021/12/16

Read more

PR post reshared by Bioprocess international

2021/12/14

Read more
【网站地图】